SCHEMBL24193602

SCHEMBL24193602

CC(C)CCCNC(=O)CCCCCC(C)(C)C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 2/20 0.43
NAMPT P43490 1/20 0.43
CNR2 P34972 1/20 0.43
FAAH O00519 3/20 0.42
LMNA P02545 1/20 0.42
PKM P14618 1/20 0.42
DNM1 Q05193 2/20 0.41
ALDH1A1 P00352 1/20 0.41
HPGD P15428 1/20 0.40
CASP2 P42575 1/20 0.40
TSHR P16473 2/20 0.39
MEN1 O00255 1/20 0.38
CYP1A2 P05177 1/20 0.38
POLB P06746 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
BLM P54132 1/20 0.38
PMP22 Q01453 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24907175 0.95 NAMPT (0.45) CNR1NAMPTCNR2FAAHLMNA
SCHEMBL28340875 0.95 NAMPT (0.45) CNR1NAMPTCNR2FAAHLMNA
SCHEMBL24490138 0.92 LMNA (0.50) CNR1NAMPTCNR2FAAHLMNA
SCHEMBL24950257 0.90 LMNA (0.51) CNR1NAMPTCNR2FAAHLMNA
SCHEMBL23788658 0.89 CNR1 (0.44) CNR1NAMPTCNR2FAAHLMNA
SCHEMBL22664216 0.86 CASP2 (0.52) FAAHDNM1ALDH1A1CASP2TSHR
SCHEMBL22664245 0.86 CASP2 (0.52) FAAHDNM1ALDH1A1CASP2TSHR
SCHEMBL10633582 0.86 CASP2 (0.52) FAAHDNM1ALDH1A1CASP2TSHR
SCHEMBL25746269 0.86 ALDH1A1 (0.43) CNR1NAMPTCNR2FAAHLMNA
SCHEMBL24948947 0.85 ALDH1A1 (0.48) CNR1NAMPTCNR2LMNAPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220009916-A1 ACETYLATION WRITER INHIBITOR DEVELOPMENT AND USES THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2022-01-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220009916-A1 ACETYLATION WRITER INHIBITOR DEVELOPMENT AND USES THEREOF EP300, KAT2A, HDAC2 CNR1 2876/4885NAMPT 459/4885CNR2 3102/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.